Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis
Epidermal Growth Factor is a protein that promotes epidermal cell (cells from the outer layer of skin) growth. EGF binds to the surface of epidermal cells to a protein called Epidermal Growth Factor Receptor (EGFR). When EGF binds to EGFR this triggers reactions that cause the cells to grow and multiply. The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity and can be found on the surface of many different types of cancer cells in high amounts. Therefore, in addition to its physiological function, EGFR plays a key role in human cancer. EGFR has been a therapeutic target for many cancers including lung cancer, colorectal cancer, breast cancer, thyroid cancer, and pancreatic cancer.
Activation leads to downstream signaling in the form of several signal transduction cascades. These include primarily the JNK, Akt, and MAPK pathways; activation of these leads to cellular proliferation via DNA synthesis. EGFR has become of prime interest for anti-cancer drug investigation. Some drugs, such as gefitinib and erlotinib, are directed specifically against the EGF receptor. Anti-EGFR drugs are either monoclonal antibodies that prevent growth factor binding or tyrosine kinase inhibitors that inhibit the signaling pathways. In order for a patient to be eligible to receive these drugs, it must be shown that the patient’s tumor possesses increased expression or activity, and this is the role of EGFR testing. Unfortunately, many patients develop resistance to a drug after a period of therapy, and as of 2010 there is no consensus on how to treat resistant tumors.
Non-small cell lung cancer (NSCLC) is a cancer that has been identified with high amounts of EGFR. Non-small cell lung cancer makes up the majority of lung cancers. This is significant because lung cancer is the leading cause of cancer death in men and women. In evaluation of treatment of NSCLC patients, tissue samples were evaluated for EGFR. It was noted in these studies that EGFR mutation is a relatively good predictor of treatment response. NSCLC patients that were positive for EGFR mutation were more likely to respond to therapies that target the EGFR pathway. In colorectal cancer, the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. In breast cancer, EGFR levels are also high and are a good therapeutic target. Therefore, analysis for EGFR mutation is significant in therapeutic treatment and disease management.
- To determine eligibility for cetuximab (Erbitux^TM ) and other EGFR target therapy treatment in patients with Non-Small Cell Carcinoma
- To evaluate which lung cancer patients might benefit from anti-TKI therapy targeted specifically toward the epidermal growth factor receptor tyrosine kinase.
- To determine eligibility for cetuximab (Erbitux™’) treatment in patients with advanced metastatic colorectal cancer.
EGFR is reported as negative/normal or increased. The specific form of the report depends upon the methodology employed, either genotyping, immunohistochemistry or fluorescence in situ hybridization.
- Negative results for EGFR mutations might indicate no respond to EGFR-targeted therapies.
If positive or over expressed indicates good candidate for therapy treatment.
- If positive for EGFR mutations, especially if occurring in the kinase domain (exons 18−21), it will most likely indicate constitutive activation of the RAS/MAPK signaling pathway; therefore, EGFR activating mutation suggests that this patient may respond to EGFR-targeted therapies.
Negative (Negative for mutation analyzed)
Negative results for EGFR mutations might indicate no respond to EGFR-targeted therapies.
Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.
- J Natl Cancer Inst. 2017 Jun 1;109(6). [PMID: 28376144]
- Int J Cancer 2011;131(5):E822−829. [PMID: 22161771]
- J Clin Oncol. 2008;26:3351-3357. [PMID: 18612151]
- Clin Cancer Res. 2006 Dec 15;12(24):7222-31. [PMID: 17189393]
- Int J Radiat Oncol Biol Phys. 2004; 59 (2 Suppl): 21-6. [PMID: 15142631]
- J Clin Invest. 2007; 117 (8): 2051-8. [PMID: 17671639]
- Proc Natl Acad Sci USA. 2004 Sep 7;101(36):13306-11. [PMID: 15329413]
- Drugs Today (Barc). 2005 Feb;41(2):107-27. [PMID: 15821783]